Core Competency
Qizheng Tibetan Medicine Wins the “14th China Listed Companies Investor Relations New Media Award”
Release time:
2023-05-26 10:48
On May 25, the 14th “Tianma Award” Summit Forum, hosted by the Securities Times, was held in Chengdu. During the forum, the winners of this year’s Tianma Awards were officially announced. Qizheng Tibetan Medicine stood out from over 1,000 listed companies and won the “Investor Relations New Media Award” for its outstanding performance in leveraging new media to enhance the quality of the company’s investor relations management.
Currently, China’s capital market reform has entered a new stage, and it will gradually shift from “China Speed” to “China Quality.” Investor relations management is an essential component of listed companies’ participation in the capital market. The quality of investor relations management by listed companies is a key indicator of their corporate governance standards; it not only shapes the prospects for high-quality development of China’s capital market but also directly affects the vital interests of the vast number of small and medium-sized investors.
Qizheng Tibetan Medicine places great importance on corporate governance and pays close attention to the quality and standards of investor relations management. It regards the protection of small and medium-sized investors as a key guiding principle and crucial lever in its investor relations management efforts. Faced with new circumstances and a new landscape, the company is, on the one hand, “strengthening its internal capabilities” to build responsible competitiveness, and on the other hand, actively embracing change and promoting the digital transformation of its investor relations management work.
Qizheng Tibetan Medicine is investor-centric and, driven by the need to provide investors with comprehensive and timely information on the company’s production, operations, and other relevant matters, has established a multi-channel investor engagement platform that includes the WeChat official account “Qizheng Tibetan Medicine Investor Relations,” the WeChat mini-program “Qizheng Tibetan Medicine Investor Relations,” the dedicated “Investor Relations” section on Qizheng Tibetan Medicine’s official website, and the official Weibo account @QizhengTibetanMedicine. Leveraging digital tools to the fullest extent, we are meticulously cultivating this investor-focused media ecosystem to better serve our investors.
Since its launch in 2021, the “Qizheng Tibetan Medicine Investor Relations Platform” WeChat official account has published 73 posts, attracting nearly 1,500 investors and generating over 35,000 views. The company has held four earnings conference calls via the “Qizheng Tibetan Medicine Investor Relations” WeChat mini-program, with a total of more than 430 investors participating online. Additionally, the company has been sharing investor education content on its official Weibo account @QizhengTibetanMedicine, helping investors develop and strengthen their awareness of rational investing. In accordance with the China Securities Regulatory Commission’s newly revised “Guidelines for Investor Relations Management of Listed Companies,” the company promptly optimized the “Investor Relations” section on its official website, dynamically retrieving data from the “Qizheng Tibetan Medicine Investor Relations” WeChat mini-program to ensure real-time updates of information, thereby providing investors with a better user experience.
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO